Drug intelligence / Profile preview

rinucumab

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

Rinucumab is a fully human monoclonal antibody developed for the treatment of neovascular (wet) age-related macular degeneration. It specifically targets the platelet-derived growth factor receptor beta (PDGFRβ), acting as an inhibitor of this receptor. By blocking PDGFRβ signaling, rinucumab aims to inhibit angiogenesis and vascular leakage associated with wet age-related macular degeneration. The drug was developed by Regeneron Pharmaceuticals and has reached Phase 2 clinical trials for this indication[1][2][3].

Other names: Immunoglobulin g4, anti-(human platelet-derived growth factor receptor) (human monoclonal regn2176 heavy chain), disulfide with human monoclonal regn2176 k-chain, dimer

Targets

PDGFRB (Platelet-derived growth factor receptor beta)

Beyond the preview

Go deeper on rinucumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rinucumab.

Explore the full profile